PURPOSE: High serum levels of macrophage inhibitory cytokine 1 (MIC-1) are strongly associated with metastatic prostate cancer, suggesting MIC-1 is a biomarker for prostate cancer prognosis. EXPERIMENTAL DESIGN: We conducted a prospective cohort study of 1,442 Swedish men with a pathologically verified diagnosis of prostate cancer between 2001 and 2003. Blood was drawn either pretreatment (n = 431) or posttreatment (n = 1,011) and cases were followed for a mean time of 4.9 years (range, 0.1-6.8 years). RESULTS: MIC-1 serum levels independently predicted poor cancer-specific survival with an almost 3-fold higher cancer death rate in patients with serum levels in the highest quartile compared with men with serum levels in the lowest quartile (adjusted hazard ratio, 2.98; 95% confidence interval, 1.82-4.68). Pretreatment MIC-1 levels revealed an even stronger association with disease outcome with an 8-fold higher death rate in the highest compared with the lowest category (adjusted hazard ratio, 7.98; 95% confidence interval, 1.73-36.86). Among patients considered to have localized disease, MIC-1 significantly increased the discriminative capacity between indolent and lethal prostate cancer compared with the established prognostic markers clinical stage, pathologic grade, and prostate-specific antigen level (P = 0.016). A sequence variant in the MIC-1 gene was associated with decreased MIC-1 serum levels (P = 0.002) and decreased prostate cancer mortality (P = 0.003), suggesting a causative role of MIC-1 in prostate cancer prognosis. CONCLUSIONS: Serum MIC-1 concentration is a novel biomarker capable of predicting prostate cancer prognosis.
PURPOSE: High serum levels of macrophage inhibitory cytokine 1 (MIC-1) are strongly associated with metastatic prostate cancer, suggesting MIC-1 is a biomarker for prostate cancer prognosis. EXPERIMENTAL DESIGN: We conducted a prospective cohort study of 1,442 Swedish men with a pathologically verified diagnosis of prostate cancer between 2001 and 2003. Blood was drawn either pretreatment (n = 431) or posttreatment (n = 1,011) and cases were followed for a mean time of 4.9 years (range, 0.1-6.8 years). RESULTS:MIC-1 serum levels independently predicted poor cancer-specific survival with an almost 3-fold higher cancer death rate in patients with serum levels in the highest quartile compared with men with serum levels in the lowest quartile (adjusted hazard ratio, 2.98; 95% confidence interval, 1.82-4.68). Pretreatment MIC-1 levels revealed an even stronger association with disease outcome with an 8-fold higher death rate in the highest compared with the lowest category (adjusted hazard ratio, 7.98; 95% confidence interval, 1.73-36.86). Among patients considered to have localized disease, MIC-1 significantly increased the discriminative capacity between indolent and lethal prostate cancer compared with the established prognostic markers clinical stage, pathologic grade, and prostate-specific antigen level (P = 0.016). A sequence variant in the MIC-1 gene was associated with decreased MIC-1 serum levels (P = 0.002) and decreased prostate cancer mortality (P = 0.003), suggesting a causative role of MIC-1 in prostate cancer prognosis. CONCLUSIONS: Serum MIC-1 concentration is a novel biomarker capable of predicting prostate cancer prognosis.
Authors: M A Díaz-Martín; M L Traba; C De La Piedra; R Guerrero; C Méndez-Dávila; E G De La Peña Journal: Scand J Clin Lab Invest Date: 1999-04 Impact factor: 1.713
Authors: Asne R Bauskin; David A Brown; Simon Junankar; Krishan K Rasiah; Sarah Eggleton; Mark Hunter; Tao Liu; Dave Smith; Tamara Kuffner; Greg J Pankhurst; Heiko Johnen; Pamela J Russell; Wade Barret; Phillip D Stricker; John J Grygiel; James G Kench; Susan M Henshall; Robert L Sutherland; Samuel N Breit Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: Fredrik Lindmark; S Lilly Zheng; Fredrik Wiklund; Jeannette Bensen; Katarina Augustsson Bälter; Baoli Chang; Maria Hedelin; Jonathan Clark; Pär Stattin; Deborah A Meyers; Hans-Olov Adami; William Isaacs; Henrik Grönberg; Jianfeng Xu Journal: J Natl Cancer Inst Date: 2004-08-18 Impact factor: 13.506
Authors: Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: A W Partin; S Piantadosi; M G Sanda; J I Epstein; F F Marshall; J L Mohler; C B Brendler; P C Walsh; J W Simons Journal: Urology Date: 1995-05 Impact factor: 2.649
Authors: David A Brown; Kenneth W Hance; Connie J Rogers; Leah B Sansbury; Paul S Albert; Gwen Murphy; Adeyinka O Laiyemo; Zhuoqiao Wang; Amanda J Cross; Arthur Schatzkin; Mark Danta; Preeyaporn Srasuebkul; Janaki Amin; Matthew Law; Samuel N Breit; Elaine Lanza Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-12-05 Impact factor: 4.254
Authors: A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin Journal: Semin Cancer Biol Date: 2015-03-06 Impact factor: 15.707
Authors: R J E Skipworth; D A C Deans; B H L Tan; K Sangster; S Paterson-Brown; D A Brown; M Hunter; S N Breit; J A Ross; K C H Fearon Journal: Br J Cancer Date: 2010-01-26 Impact factor: 7.640